Determine the necessary mass, volume, or concentration for preparing a solution.
10mM in DMSO 최소한의 기준선 간섭이 필요한 민감한 크로마토그래피 및 분석 워크플로우용.
Store at -80°C Dry ice packs + Cold packs 출고. 정확한 사양은 로트별 COA를 확인하세요.
SDS, COA, 데이터시트, 사양서를 다운로드할 수 있습니다. 로트별 COA는 로트 번호 조회를 통해 확인할 수 있습니다.
크로마토그래피, 유기 합성 및 교차 커플링 반응 분야의 동료 심사 논문 0편에서 인용되었습니다.
PI3Kα-IN-4 is a potent, selective and orally active inhibitor of PI3Kα , with an IC 50 of 1.8 nM. PI3Kα-IN-4 has antitumor activity
In Vitro
PI3Kα-IN-4 (compound 10) inhibits PI3Kα, β, δ, and γ, with IC 50 s of 1.8, 271.0, 13.9, and 13.8 nM, respectively in kinase assays. PI3Kα-IN-4 inhibits PI3Kα, β, δ, and γ, with IC 50 s of 12.1,1393, 183, and >10000 nM, respectively in cell based assays. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
PI3Kα-IN-4 (compound 10) (30 mg/kg; p.o. once daily for 21 d) achieves the best efficacy, which could inhibit tumor growth by 73.0% in mice . PI3Kα-IN-4 (15-40 mg/kg; p.o. once daily for 30 d) dose dependently suppresses tumor growth by 62.5% (15 mg/kg), 86.0% (30 mg/kg) and 90.7% (40 mg/kg), respectively in mice . PI3Kα-IN-4 (15-40 mg/kg; p.o. once daily; 1-4 h) inhibits the phosphorylation of Akt in a dose- and time-dependent manner in vivo . PI3Kα-IN-4 shows high C max (mouse 22167, rat 2327 nM) and good bioavailability (mouse 59.4%, rat 46.9%) following oral administration (mouse 10, rat 3 mg/kg) . PI3Kα-IN-4 shows t 1/2 (mouse 0.99, rat 1.22 h) and low plasma clearance (mouse 4.16, rat 5.28 mL/min/kg) following intravenous injection (mouse 1, rat 1 mg/kg) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: BT-474 subcutaneous xenograft mice Dosage: 30 mg/kg Administration: P.o. once daily for 21 days Result: Inhibited tumor growth by 73.0% and could be tolerated.
IC50& Target:PI3Kα 1.8 nM (IC 50 )
위험성, 취급, 보관 및 규제 준수를 포괄하는 종합 문서.
<<<<<<< HEAD SDS 다운로드 → ======= SDS 다운로드 → >>>>>>> release248-p3